GeneSilico™ is an AI-driven bioscience company that revolutionizes cancer care by integrating multi-modal and multi-omics analysis, therapy matching, and patient monitoring through our gSage™ platform. Combining ultra-sensitive Deep Precision™ NGS panels with AI technology, we transform complex test results into clear, prioritized treatment and trial recommendations, cutting decision times from days to minutes. Our platform not only delivers rapid, high-confidence insights but also enables real-time, adaptive therapy adjustments based on ongoing molecular and clinical data. This approach makes precision oncology faster, more personalized, and accessible to healthcare providers of all sizes, addressing the critical challenge of managing vast, complex molecular data.
Today’s cancer care faces a huge gap: demand for effective treatments is soaring, but current methods can’t keep up. GeneSilico’s platform uses AI to deliver precise, affordable therapies, helping more patients survive and improve their quality of life. Traditional interpretation of genomic data is slow and noisy, limiting treatment options and outcomes. Tumor changes and complexity require real-time analysis, but most clinics lack the tools for this. With advances in genomics and biology producing massive amounts of data, clinics struggle to interpret it all — static rules aren’t enough anymore. GeneSilico addresses this by providing fast, adaptive, data-driven insights that improve decision-making, reduce costs, and speed treatment. It’s a critical step towards more personalized, effective cancer care that’s needed now more than ever.
GeneSilico offers highly precise, actionable cancer insights with its tumor-specific NGS panels that link genetic findings directly to FDA-approved therapies. It delivers up to 3 times more treatment options compared to broader panels, helping clinicians choose the best, most relevant therapies.
Our platform integrates AI agents that analyze genomics, images, radiology, and patient data to generate fast, clear treatment recommendations with full transparency. This digital tumor board cuts decision times from months to days or even minutes, while ensuring safety and continuous learning from patient outcomes.
GeneSilico also reduces costs by tailoring therapies to regional drug prices and nearby clinical trials. Its combined genomics, RNA, and structural modeling produce high-quality, comprehensive insights that support personalized, affordable cancer care. Plus, our patient app tracks outcomes and symptoms daily, empowering patients and enabling real-time treatment adjustments for better safety and results.
We launched successfully in India, gaining strong market fit with initial revenue from a large, price-sensitive cancer market. Partnering with key distributors like Karkinos, Apex, and Anand, we’re connecting with hundreds of oncologists and tracking thousands of patients—demonstrating fast, scalable adoption and effective integration into clinical workflows. Our influential medical team from Omega and HCG Hospitals accelerates adoption through education and credibility.
Our strategic partners— Reliance, Genotypic, Accenture, and Texas Oncology—support growth and international expansion. We're staging pilots in the US and exploring opportunities like the $50B Rural Health Fund to bring affordable, AI-driven cancer care to underserved communities. These proven signals confirm GeneSilico’s rapid growth and potential for global impact.
gSage’s competitive advantage lies in its integrated, disease-specific, high-sensitivity panels combined with AI-driven workflows, providing fast, precise, and actionable insights tailored for local markets like India. Unlike broad-panel companies such as Foundation and Guardant, or data-centric models like Tempus, gSage focuses on real-time, operational solutions optimized for point-of-care and scalable deployment. While tech giants like Microsoft and Google pursue early detection, gSage’s strength is leveraging deep clinical relationships and high-quality, real-world data—especially in India—to deliver more accurate, adaptable, and globally relevant precision oncology solutions. Its upcoming US open gSage launch will further accelerate global adoption, driven by insights derived from complex Indian genomic data.
GeneSilico will earn revenue through a mix of B2B and B2C channels. We partner with hospitals, clinics, and pharma companies to provide NGS testing integrated with our AI platform, offering subscriptions that improve diagnosis and treatment decisions. We will also generate income from value-based payments tied to cost savings and better patient outcomes, which can be reimbursed by payers and healthcare systems. Additional revenue will come from advanced analysis tools, continued case analytics, patient engagement plans, and anonymized data analytics for research. Our flexible model will adapt across markets, ensuring sustainable growth.
gSage is designed to deliver measurable improvements in cancer care efficiency and outcomes. While not all of these currently exist yet, the targeted key metrics include: reducing time-to-treatment by 20–40%, allowing faster patient access to therapies; increasing guideline-concordant testing and therapies by 15–25%, ensuring better treatment alignment; and providing high-confidence resistance markers in over 60% of cases, helping clinicians avoid ineffective therapies. It also will streamline prior authorization processes, cutting cycle times by 30–50% and decreasing denials by 20–40%. Trial enrollment efficiency is expected to improve with a 10–15% increase in patient consent rates and a 5–10% better follow-through to treatment, while re-biopsies and re-tests after inconclusive results could decrease by 15–25%, reducing invasive procedures. Additionally, the platform aims to lower adverse event-related ER visits and hospital stays by 10–15%, improving safety and reducing costs. Staff productivity benefits include reclaiming 30–60 minutes per case by streamlining orders, authorizations, and documentation, supporting faster, more personalized, and high-quality patient care.
Our plan has started in India by working with local hospitals and oncology centers, proving our clinical value and generating initial revenue. Next, we’ll expand into the US, leveraging open AI models, followed by entry into the Middle East and Europe, tailoring strategies to regional needs. During this time, we’ll build recurring revenue through AI subscriptions, integrated testing, and patient support. We’re also pursuing larger funding rounds to scale operations, deepen partnerships, and accelerate global deployment. Throughout, our focus will be on developing reimbursement pathways, expanding enterprise collaborations, and growing our sales network to ensure long-term, sustainable revenue growth.
We’re offering a SAFE with a 20% discount on a future Series A, capped at $60M, to support our growth. Funds will help us launch in India, build distributor relationships, develop new NGS panels, improve gSage, and secure more patents / publications. In Q4 2025, we’ll launch Open gSage, an AI that helps doctors personalize cancer treatment in real time, boosting our competitiveness and growth.
In 2026, we’ll raise a Series A to scale globally, expand into new markets, validate clinical results faster, and develop patient-focused features like digital twins. This will also support marketing, partnerships, and organizational growth, positioning us as a leading global cancer care platform.
- Who we are: GeneSilico™ is an AI/Bioscience company with our gSage™ platform, integrating multi-modal and multi-omics analysis, therapy matching, care coordination, and patient monitoring across the cancer care continuum. It enables AI-driven, personalized treatments at scale through deep multi-omics profiling, real-time adaptation, and continuous learning. GeneSilico makes precision oncology accessible to providers of any size worldwide, ushering in a scalable, AI-powered era of cancer care.
- What we do: We combine our focused, ultra-sensitive cancer-specific Deep Precision™ NGS (Next Generation Sequencing) panels with our clinician-facing conversational agentic AI platform, gSage™, which transforms test results into clear, prioritized cancer treatment and trial recommendations for oncologists. Our solution reduces decision support timelines from days to minutes, enabling faster, more precise clinical decisions and improved patient outcomes. Additionally, we are connecting precision oncology, predictive omics technologies, and sensory intelligence from pathology and radiology with agentic AI to build a digital tumor board — optimizing patient treatments and extending life.
- Why it matters: Clinics and drug developers have vast amounts of molecular data they struggle to act on. Advances in protein structure modeling and error-suppressed sequencing allow us to transform variants into high-confidence treatment hypotheses. GeneSilico integrates lab, analytics, and software to deliver these insights quickly at the point of care. Additionally, it enables dynamic tuning of treatment regimens based on real-time molecular and clinical data, ensuring more personalized and adaptive patient care.
-
- Clinical Supply vs. Patient Demand - Narrowing the gap between the effective supply and the enormous demand of cancer services by utilizing AI to get precise, cost-effective treatments to improve survivability and extend quality of life.
- Slow Interpretation: Precision oncology is becoming mainstream; oncologists and payers expect informed treatment selection, however slow, noisy interpretation pipelines reduce therapy options and worsen outcomes.
- Inadequate Modeling - Poor Outcomes: Without better omics-based/computer vision based treatment response prediction models and target matching, many patients miss effective therapies or receive ineffective/expensive treatments.
- Resistance and Heterogeneity: Tumor evolution inter/intratumor heterogeneity make static rules obsolete; real-time, high-resolution interpretation is needed to stay ahead of resistance.
- Data Explosion: As sequencing, structural biology, and multi-omics technologies (WGS, WES, scRNA-seq, mass spectrometry) become more affordable, data volume is rapidly outpacing interpretive capacity. While these advanced molecular and data-rich approaches hold great promise for new insights, most clinics lack the tools and infrastructure to efficiently interpret and act on the overwhelming flow of genomics and clinical data now available. A static “one-size-fits-all” decision framework is no longer sufficient; we address this dynamic landscape with adaptable, real-time solutions to enable personalized, data-driven cancer care.
- Economic Pressure: GeneSilico helps providers reduce costs by enabling more accurate, personalized treatments that lead to better outcomes and fewer complications. It speeds up diagnosis and therapy decisions, allowing for earlier interventions and reducing unnecessary treatments. The platform also increases patient throughput and trial efficiency, saving time and resources, while real-time monitoring helps avoid costly re-admissions and overuse of resources. Overall, it supports more affordable, effective cancer care at scale.
- Clinical Decision Support at the Point-of-Care: Unlike commercial GPT services, gSage AI is based grounded in expert curated, trustworthy medical facts. gSage enables rapid, accurate insights directly at the point of care, helping clinicians make informed decisions swiftly. This reduces diagnosis time, improves treatment precision, and enhances patient outcomes, addressing the urgent demand for real-time, personalized health care solutions.
- Predictive Accuracy for Biological Interactions: GeneSilico uses tumor omics data to provide high-fidelity simulations of drug response in patients, taking into account tumor specific molecular traits.
- Integration of Personalized Medicine: gSage accounts for individual patient variability. It enables personalized simulations, paving the way for tailored therapies.
- Regulatory & Technological Convergence: Regulators are increasingly receptive to computational evidence; advances in AI/ML and high throughput omics make high value solutions possible now.
- Agentic Care Operations (operating system): By owning the bioinformatics, workflow, and interpretation software, gSage becomes a recurring SaaS platform and clinician‑in‑the‑loop multi‑agent system that does far more than deliver test reports: it supports test ordering and biopsy scheduling, closes biomarker gaps, drafts prior‑authorization packets, pre‑screens clinical trials, and prepares tumor‑board briefs while preserving clinician oversight and sign‑off to ensure safety and trust. Its multi‑tool capabilities include precision oncology report interpretation, clinical trial matching, in‑silico drug‑response simulation, nearest‑neighbor patient comparisons from global datasets, radiology/pathology reporting and image Q&A, and instant access to clinical guidelines — together driving faster time‑to‑treatment, higher guideline adherence, streamlined workflows, reduced administrative burden, and safer, more personalized patient care.
- GeneSilico’s Deep Precision NGS: Cancer-specific panels (for example, a 68 gene breast cancer test) that link biomarkers and genetic alterations to FDA approved therapies, and clinical trials, flag drug metabolism, efficacy and DNA repair implications, and surface investigational or nonstandard options when appropriate.
- Deep Precision NGS Actionability - Our tumor‑focused panel design delivers a 70–80% actionability rate, so most patients have at least one actionable finding and clinicians see up to 3x more potential therapy options for a given cancer type. By contrast, broad comprehensive‑cancer panels (which include many genes irrelevant to a single indication) typically show lower actionability for single‑cancer use (around 50-60%), while very small hotspot panels can miss cancer‑specific targets and reduce the chance of actionable insights. Validated and benchmarked against standard of care, our assays detect mutations down to sub‑1% allele frequency using ~2000X unique coverage of the clinically relevant genes — substantially deeper than the ~500X coverage common in many comprehensive genomic profiling (CGP) assays.
- Deep Precision NGS + gSage: Provides fully cited responses from NCCN, ASCO, ESMO, labels, and trials, including counterfactuals like toxicity trade-offs, and flag off-label uses with payer risk, offering transparency and reliability that surpass generic LLM assistants, thereby building trust within tumor boards. gSage also provides information on drug availability in local markets, with their pricing.
- Digital Tumor Board - Orchestrating AI agents that collaboratively analyze genomics, pathology whole-slide images, radiology, and EHR data to generate comprehensive, cited recommendations with uncertainty estimates and alternative options. It provides contextualized treatment and therapy options, decision pathways, and continuous learning from patient outcomes to refine and improve future recommendations.
- Safe, Auditable, learning AI agentic workflow: a closed loop (hypothesis → verification → learning) with full provenance (traceability) — attractive to providers, payers, pharma and attractive for CDx (companion diagnostics) partnerships. Building safe, auditable, clinical-grade agentic loops that also produce regulatory grade evidence and track provenance is technically and procedurally difficult.
- Local Cost Optimization: gSage helps providers lower the cost curve of cancer therapy while reducing mortality through a streamlined, low-burden point-of-care system. It enables patients to identify the most appropriate, cost-effective therapies by listing ranked options with side effects and localized costs. Its localized approach improves drug pricing accuracy, access to nearby trials, and overall cost savings, making treatment more affordable and tailored to each community's needs. Additionally, gSage offers patient genetic and financial counseling, education support, and promotes value-driven treatment choices. Its hyper-local focus further enhances cost efficiency by leveraging region-specific resources and ensuring treatments align with local healthcare ecosystems.
- Biology-to-therapeutics integration: Deep precision panel results + RNA/expression, structural modeling (protein folding, druggability pockets), pathway context, and knowledgebase evidence fused into a single interpretation output. Validated clinical data and operational characteristics that competitors can’t easily copy without major investment.
- Ground-truth curated knowledge: Validated structural pipelines and tightly integrated mapping rules — while many competitors offer genomics OR structure OR a knowledgebase, delivering all three with clinical reliability is difficult. GeneSilico uses expert‑curated data and a knowledge graph, backed by an in‑house Vector DB and Graph‑RAG architecture, to produce trustworthy, auditable interpretations rather than relying on generic models trained on disparate sources.
- Patient in the Loop: A patient co-pilot app that summarizes treatment options, tracks daily patient-reported outcomes and toxicity, and syncs with devices to provide real-time feedback for dose adjustments and early detection of adverse events, effectively closing the care loop. It supports treatment education and empowerment to help patients better understand their care, participate actively in decision-making, and improve overall treatment adherence.
- Higher Quality Outcomes: - By leveraging multi-modal interpretation of genetics, pathology, structural biology, and integrating the most recent research developments, we provide clearer, more comprehensive, and higher-value recommendations for therapy selection. This approach enhances the precision of treatment decisions, reduces uncertainty, and helps clinicians identify the most effective therapies tailored to each patient’s unique tumor profile. Ultimately, it supports better outcomes and maximizes the value of clinical insights in the therapy decision-making process.
-
Commercial launch in India - We have successfully launched in India, establishing product-market fit and operational readiness with our first revenue stream in a large, price-sensitive oncology market. We are working with multiple distributors representing hundreds of oncologists and OB/GYNs, tracking hundreds (and soon thousands) of patients on the platform, with a consistent 3–4 week turnaround time and early signs of substantial growth. This demonstrates our ability to effectively commercialize, navigate local regulations, and scale in a high-impact market. Our highly influential medical team in India has been key in driving these efforts and expanding our reach.
Sequencing and Distribution -Our adoption signals are strong and demonstrate a robust ecosystem supporting rapid growth. Karkinos is serving as a key sequencer, while partners like Apex, Anand, and Karkinos act as distributors, providing embedded access to clinical workflows and handling large patient volumes. Partner validation and integration into existing clinical processes boost credibility and ensure seamless adoption. Having a recognized oncology platform partner accelerates market entry by offering established distribution channels, clinical credibility, and increased referral volume. Our scalable go-to-market strategy extends beyond direct sales, with active distributor agreements covering multiple territories, minimum purchase commitments, and channel onboarding timelines, resulting in channel-led sales. This approach significantly reduces customer acquisition costs and enables quick scaling through partnerships.
Medical Team Influence and gSage in India – The GeneSilico medical team are doctors from Omega Cancer Hospital and HCG Cancer Hospital and are highly influential in India, playing a crucial role in advancing cancer care and education. They are actively collaborating with us and our distributors to conduct Clinical Medical Education (CMEs), helping to shape clinical practices and promote the adoption of innovative solutions. These respected physicians are widely followed within the oncology community, further enhancing the credibility and reach of our platform. As no other organization has introduced AI-driven gSage type solutions of this scale in India, there is strong interest and enthusiasm from the medical community, positioning us as pioneers in transforming cancer care in the region.
Strategics and Advisors – Our strategy and advisory team includes leading experts and key partners to accelerate growth and innovation. Reliance, a major Indian conglomerate and owner of Karkinos, provides strategic support and market access in India. Genotypic, a large NGS provider, has expressed strong interest in utilizing gSage for interpretation of their panels, offering opportunities for CDx collaborations. Additionally, we have top strategic advisors from Accenture Health and Texas Oncology on our advisory board, bringing deep expertise in healthcare transformation, technology, and clinical operations. We are actively staging pilots and leveraging the momentum gained from our India presence to build US-based collaborations, industry partnerships, and clinical implementations, positioning us for rapid expansion and impactful adoption in global markets.
Accenture and Rural Health Transformation Fund -The $50billion Rural Health Transformation Fund is designed to strengthen health care systems in underserved US areas through investments in infrastructure, telehealth, and advanced diagnostics. GeneSilico can play a key role by providing scalable, affordable AI-driven cancer care that supports early diagnosis, personalized treatment, and improved outcomes in rural regions. By streamlining workflows, expanding access to cutting-edge diagnostics, and supporting local providers, we can help reduce disparities and build sustainable, technology-enabled healthcare ecosystems. Currently, Accenture is in early-stage discussions with us about a potential partnership to leverage our solutions and maximize the impact of these investments in rural communities.
Monetization Overview: GeneSilico monetizes through a comprehensive mix of B2B and B2C models, engaging oncologists, hospitals, payers, pharma, and patients. Revenue streams include partnerships with hospitals and clinics for NGS test integration and AI subscription services that enhance diagnostics and treatment decisions. We can offer value-based outcomes by demonstrating cost reductions through improved treatment accuracy, which can be reimbursed directly by payers and healthcare systems. Our direct sales team and channel partners handle sales to hospitals, clinics, and pharma, with options for upfront payments, subscriptions, and reimbursement models. Upsell opportunities include advanced AI analysis tools, extended case analytics, and patient-in-the-loop subscription plans that foster continuous engagement. We also generate anonymized, de-identified analytics for research and insights, creating additional revenue streams. Our flexible business model can adapt to various healthcare markets, ensuring scalable and sustainable monetization.
Approach for 24-36 months - Our approach over the next 24–36 months is to establish a scalable path to revenue growth by initially focusing on ago-to-market (GTM) strategy in India, working closely with local hospitals, oncology centers, and key partners to demonstrate clinical value and generate early revenue. Following this, we will expand into the US market, leveraging proven models, and then enter the Middle East and European markets, adapting our strategies to regional needs. Concurrently, we will develop recurring revenue streams through AI subscriptions, integrated NGS testing, and patient-in-the-loop services, with opportunities for upselling advanced analytics and expanded features. We are also working on securing a larger Series A funding round to provide the necessary capital for scaling operations, expanding partnerships, and accelerating global deployment. Throughout this period, we will focus on building reimbursement pathways, deepening enterprise collaborations, and expanding our network through direct sales and channel partners to ensure sustainable, long-term revenue growth.
Current SAFE Note Seed Round Opportunity - We are currently offering a SAFE Note with a 20% discount on a Qualified Series A and a $60M valuation cap. This note supports our rapid growth and product development efforts. Our immediate focus is on executing our go-to-market strategy in India, establishing key distributor relationships and expanding commercial traction. Simultaneously, we are actively developing multiple NGS panels (lung, ovarian, prostate) and enhancing the gSage platform to improve accuracy, usability, safety, and clinical utility. We are also advancing our compliance processes, securing relevant patents, and publishing scientific research to strengthen our credibility and intellectual property position. Additionally, other parts of our roadmap involve developing patient-in-the-loop capabilities to enable continuous engagement and real-time data collection. These efforts, combined with regulatory validation and broader clinical integration, position us to accelerate growth, build strategic assets, and lay the groundwork for global expansion and long-term value creation.
Upcoming Series A inQ1/Q2 2026 (Significant up round expected from the current SAFE seed round) – An upcoming Series A round will fully fund our global scale-up, advanced product development, and market expansion, building on the foundation established through the SAFE stage. This early-stage investment enables us to accelerate key milestones by expanding our development and commercialization efforts worldwide. It will support scaling our NGS panels and gSage platform, expediting clinical validation studies in the US, Middle East, and EU, and rolling out clinical studies in these regions. Additionally, it will strengthen our compliance efforts, secure patents, publish scientific research, and develop patient-in-the-loop capabilities for real-time engagement. We will further refine the Precision Oncology LLM, develop patient digital twins and personalized treatment solutions, validate additional Deep Precision panels, and scale infrastructure, regulatory, and legal operations. This capital also facilitates broad go-to-market efforts across all markets, along with investments in PR, partnerships, marketing, and organizational growth as we transition from founder-led to a team-led company. Overall, this funding will enable us to achieve rapid growth, technological leadership, and strategic impact on a global scale, positioning us for long-term success.
- gSage is an AI-powered, multi-modal decision support platform that integrates genomics, pathology, radiology, and clinical data—leveraging cBioPortal’s database of over 300,000 patient genomes—to deliver highly personalized, evidence-based treatment recommendations. It includes patient-like-me matching to identify the most relevant therapies and trials tailored to individual tumor profiles. Using deep learning, multi-omics analysis, and real-time data, gSage provides clear insights, including therapy options, trial matching, and outcome predictions. Continuously learning and adapting, gSage improves decision-making, patient outcomes, and accelerates precision oncology, making it vital for oncologists, hospitals, and researchers seeking scalable, accurate cancer care solutions.
- gSage and Oncologist workflow - gSage streamlines the oncologist workflow by integrating sample ordering, automatic ingestion and analysis of NGS, RNA, IHC (Immunohistochemistry), and clinical data to generate a prioritized, evidence-based report with actionable findings, recommended therapies, and trial options. Oncologists review and drill into the report—either solo or with a tumor board—filtering by availability and contraindications to make informed decisions. The platform will ultimately support ordering follow-up tests, prescriptions, trial referrals, and payer evidence, while outcome data feeds back to improve future recommendations. Designed for point-of-care, gSage seamlessly integrates with EMR and LIS systems, provides fast turnaround times, and reduces interpretation burden, enabling more confident, efficient, and targeted treatment decisions.
- What makes Deep Precision different - What makes Deep Precision GeneSilico NGS different is its focus on specific tumor types like breast, lung, ovarian, and prostate, selecting genes and regions that are most relevant for treatment and clinical trials. This means it gives more useful, actionable results at a lower cost compared to broad exome sequencing. Its ultra-high sensitivity, thanks to advanced tools like molecular barcoding (Unique Molecular Identifiers, UMI), can detect low-frequency variants in cell-free DNA (cfDNA) and formalin-fixed paraffin-embedded (FFPE) samples, which is important for tracking minimal residual disease (MRD) and resistance. The platform ensures consistent, reliable results with deep and even coverage and strict quality checks (such as on-target percentage, uniformity, and duplicate rate). It detects many types of genetic changes—such as single nucleotide variants (SNVs), insertions/deletions (indels), copy number variations (CNVs), and some structural variations (SVs)—and offers optional modules for tumor mutational burden (TMB) and microsatellite instability (MSI). Built with proven automation, it provides fast, certified results suitable for point-of-care use, helping clinicians make accurate decisions quickly in real clinical settings.
- Early adoption of Deep Precision NGS and gSage in India - Offers significant value by enabling more precise, affordable, and rapid cancer detection and treatment decisions in a country with a large, diverse, and underserved patient population. Implementing these advanced tools early can enhance diagnostic accuracy, improve patient outcomes, and reduce costs by focusing treatments on actionable targets and minimizing ineffective therapies. It also helps build local clinical expertise, establish regulatory pathways, and create a scalable model for deploying precision oncology at a national level. Furthermore, working with distributors who have access to thousands of oncologists and referring physicians accelerates adoption by rapidly expanding clinical reach, referrals, and real-world data collection across diverse populations. This combination of local expertise, extensive referral networks, and high-quality data generates a robust data moat, improving algorithm accuracy, expanding clinical evidence, and strengthening long-term competitive advantage. This strategic positioning will further accelerate GeneSilico’s validation and global expansion, establishing it as a leader in precision cancer care and driving sustained growth and innovation worldwide.
- US Staging - Bringing Deep Precision NGS and gSage to the US has the potential to significantly impact by offering highly accurate, disease-specific genomic testing and decision support at a scale that can improve patient outcomes, reduce costs, and drive adoption of precision oncology. This introduces a disruptive, innovative approach in the US market, strengthening GeneSilico’s position as a global leader in AI-driven cancer diagnostics. To stage our entry effectively, we leverage the momentum, learnings, and data generated from early deployments in India, which help refine our technology, validate clinical utility, and establish strategic partnerships. Additionally, we are developing pilot collaborations with Texas Oncology and leveraging our partnership with Accenture to fast-track validation, clinical integration, and commercialization. These pilots and partnerships will demonstrate real-world effectiveness, build credibility, and accelerate regulatory approval and clinician adoption in the US, lowering entry barriers and reducing time-to-market while expanding our global footprint efficiently.
- Middle East Gateway - The Middle East is a highly complementary market to India, offering strategic advantages for GeneSilico’s growth and expansion. Both regions share a growing healthcare infrastructure and a strong emphasis on adopting advanced medical technologies, creating opportunities for integrated cancer diagnostics and personalized treatment solutions. While India provides a vast, diverse, and rapidly expanding patient base for early validation, clinical testing, and scalable deployment, the Middle East offers a high-income market with advanced healthcare systems and a focus on cutting-edge precision oncology. Together, these regions form a balanced approach: India builds volume, regional expertise, and data diversity, while the Middle East enables premium pilot projects, faster regulatory approvals, and access to affluent markets. Expanding in both markets allow us to leverage India’s cost-effective scaling capabilities and Middle East’s strategic positioning as a gateway to Europe, Africa, and other parts of Asia, creating a powerful, synergistic pathway for global growth.
- Open gSage (will be activated in Q4’25): The gSage Open Onco AI platform supports clinicians in delivering personalized, cancer-specific treatment plans. Its Oncology GPT answers natural language questions about treatment options, latest research, and condition management, all guarded by trained AI to ensure bias, safety, security, and compliance. It analyzes patient data to provide deep research insights, generate summaries, and recommend evidence-based therapies. Clinicians can securely share findings with their care team and collaborate with other specialists, similar to social platforms. HIPAA-compliant and cloud-secure, it seamlessly updates treatment guidance into the patient’s EHR, enabling continuous, coordinated cancer care.
- Enterprise gSage (will be activated in Q4’25): The gSage Enterprise Onco AI platform enables healthcare organizations to deliver personalized, cancer-specific care by integrating genomics and AI into clinical workflows. It supports patient engagement, decision support, tumor board briefs, prior authorization, and payor approval—all orchestrated by AI agents to streamline operations. Once treatment decisions are made, follow-on care and treatment adjustments are also executed automatically by AI agents, ensuring continuous and adaptive patient management. The platform allows clinicians to ask detailed questions about treatment options and research, with AI ensuring bias reduction, safety, and compliance. It analyzes patient data to generate insights, treatment recommendations, and summaries while facilitating secure collaboration across teams and external specialists. Fully HIPAA-compliant and cloud-secure, gSage seamlessly integrates into existing systems, automatically updating and documenting personalized care within each patient’s EHR for ongoing, coordinated treatment.
- GeneSilico’s Core Revenue Models - Built on multiple streams that leverage its advanced diagnostic and AI platforms. The primary revenue comes from per-patient diagnostic fees for Deep Precision NGS panels, with prices tailored by geography, tumor type, sample type, and turnaround time. Recurring revenue is generated through tiered gSage platform subscriptions, providing interpretation, tumor board support, predictive care analytics, and EMR/LIS integration, which creates predictable annual recurring revenue (ARR) and reduces reliance on one-off test sales. Additional income flows from provider and lab enablement—covering setup, training, licensing, and royalties—as well as professional services like custom analyses, validation, and regulatory support. Furthermore, de-identified analytics services offer valuable insights and cohort data access to providers, payors, and pharma companies, supporting research, optimizing clinical pathways, and enabling evidence-based decision-making.
- Additional Revenue Models - For pharma and clinical trial applications, GeneSilico can offer flexible monetization strategies such as per-screen fees, subscription screening capacities, or success-based payments aligned with trial enrollment. The third-party NGS ingestion and harmonization services monetize external data integration through per-sample or per-report fees, with higher-value “premium” options for advanced reanalysis and structural modeling. These models enable GeneSilico to build a scalable, adaptable revenue base that leverages operational levers like pricing tiers, feature bundles, and volume discounts to optimize growth, expand market reach, and foster long-term partnerships across clinical, commercial, and research segments.
- Pricing Levers - GeneSilico’s platforms are designed to optimize revenue while maximizing adoption across diverse markets. These include geographic price differentiation, where prices vary between regions such as India, Southeast Asia, the US, and Europe to reflect market capacity and affordability. Tumor type premiums can be applied for complex panels or MRD add-ons, while sample type—such as cfDNA (liquid biopsy) versus FFPE (solid tissue)—also influences pricing. Turnaround speed offers a premium for expedited results, catering to urgent cases. Feature-based tiering allows for different levels of testing, from basic reports to comprehensive panels with advanced modules like fusion detection or TMB/MSI, enabling flexible pricing models for hospitals and labs. Volume discounts and commitment-based pricing further incentivize high-volume customers, while channel-specific pricing adjusts for high-throughput reference labs versus end-to-end hospital services. These levers give GeneSilico the flexibility to adapt pricing to market dynamics, customer needs, and strategic objectives, ultimately driving growth and profitability.
- GeneSilico’s go-to-market (GTM) scaling milestones - Focus on sequentially expanding adoption, validation, and revenue. The initial phase involves establishing a strong presence in India through pilot projects, building local clinical expertise, and formalizing distributor relationships to achieve expanded commercial traction. Next, we aim to validate our platform with key clinical and payer partnerships, demonstrating clinical utility and cost savings. Following validation, the focus shifts to expanding in the US through strategic pilots with leading oncology networks like Texas Oncology and leveraging partnerships such as Accenture, to accelerate regulatory approval and clinician adoption. Simultaneously, we plan to enter high-potential markets in the Middle East and Europe, leveraging India’s momentum and data advantages as proof points. Throughout this process, we will scale infrastructure, regulatory compliance, and local partnerships, while continuously refining our product and expanding our clinical and payer networks, to build a sustainable global presence within 24–36 months.
- Please reference the GeneSilico overview deck to show revenue run-rate/milestones.
- Deep Precision NGS panels are LDT approved - Deep Precision NGS approved as Laboratory Developed Tests (LDTs), ensuring they meet quality, safety, and performance standards for clinical use within specific laboratories. This certification allows us to deliver reliable, high-quality diagnostic and ingested for decision-support services in compliance with regulatory frameworks. We can sell this commercially as long as we explicitly state that their use is for research purposes only. This approach facilitates trusted deployment in healthcare settings, supports integration into clinical workflows, and maintains compliance with national requirements, while clearly communicating the intended purpose to regulatory authorities. gSage can be used with LDT cleared panels.
- Deep Precision NGS and gSage are CDSCO / NABL aligned, working towards approval - Aligned with regulatory standards such as CDSCO (Central Drugs Standard Control Organization) and NABL (National Accreditation Board for Testing and Calibration Laboratories) to ensure it meets India's strict compliance and quality requirements for diagnostic devices. It adheres to CDSCO regulations for clinical diagnostic test validation, quality control, and safety standards, facilitating regulatory approval and market access. Simultaneously, gSage’s laboratory processes and analytical validation are conducted in accordance with NABL accreditation standards, ensuring high-quality testing, accurate results, and reliable performance. This alignment promotes trust with regulatory authorities, healthcare providers, and patients, enabling gSage to operate confidently within India’s regulated healthcare ecosystem and support national efforts toward precision medicine.
- Deep Precision NGS and gSage are SaMD aligned, working towards FDA approval - Aligned with 510(k) SaMD (Software as a Medical Device) regulations, demonstrating that it meets the necessary safety, effectiveness, and quality standards set by the U.S. FDA. This alignment involves rigorous validation, risk management, and clinical validation processes to ensure the software delivers accurate, reliable, and compliant diagnostic and decision-support functions. Being 510(k)-cleared or aligned provides confidence to healthcare providers and payers that gSage’s AI-driven solutions can be safely integrated into clinical workflows, supporting regulatory approval, reimbursement, and widespread adoption in the U.S. healthcare system.
gSage targeted example metrics including, but not limited to:
- Time-to-Treatment Reduction: Expected to decrease time-to-treatment by 20–40%, enabling faster patient care and reducing delays.
- Guideline-Concordant Testing & Therapy: Anticipated to improve adherence by 15–25%, ensuring patients receive appropriate and effective treatments aligned with clinical guidelines.
- Treatment Accuracy & Resistance Flags: High-confidence resistance markers in ≥60% of cases help clinicians avoid ineffective therapies and resistance development, improving overall treatment outcomes.
- Streamlined Prior Authorization: Cycle times reduced by 30–50%, with denial rates falling by 20–40%, expediting access to therapy and easing administrative burdens.
- Trial Enrollment & Access: Match-to-consent rates are expected to increase by 10–15%, with a 5–10% improvement from consent to treatment, enhancing trial participation and personalized care.
- Reduced Re-biopsies & Re-testing: Inconclusive report re-biopsy/re-test rates decrease by 15–25%, minimizing invasive procedures and associated patient risks.
- Lower Emergency Visits & Admissions: Adverse event-related ER visits and hospital admissions decline by 10–15%, improving patient safety and reducing costs.
- Staff Productivity & Workflow Efficiency: Reclaims 30–60 minutes per case in staff time for orders, prior authorizations, and documentation, supporting faster clinical operations and high-quality, personalized patient care.
- India Lacks a True Competitor to GeneSilico - In India, the competitive landscape for gSage includes several local and international platforms offering genomic testing and clinical decision support, but few combine the integrated AI-driven insights, cancer-specific panels, and streamlined workflows that gSage provides. Companies like Strand Genomics, MedGenome, and SeraCare offer genetic testing and some level of clinical interpretation, but lack the full AI-powered decision support, real-time integration, and testing automation that gSage delivers. Additionally, most competitors focus on broad panels or exome analysis without the targeted, high-sensitivity approach optimized for specific cancer types that gSage provides. This positions gSage as a differentiated player with a significant advantage in delivering precise, scalable, and clinically actionable insights tailored for India’s unique healthcare needs.
- Competition with Tempus - Tempus is one of the main competitors in the precision oncology space, primarily offering comprehensive genomic testing, clinical data integration, and AI-driven insights. However, Tempus’s approach is quite different from GeneSilico. While Tempus focuses on building large clinical-genomic databases and providing broad molecular testing with a strong emphasis on data-driven treatment insights and clinical decision support, GeneSilico specializes in highly targeted, disease-specific panels and AI platforms like gSage that deliver real-time, actionable insights at a more granular, platform-driven level. GeneSilico’s focus on high-sensitivity, targeted panels and its emphasis on operational workflows, including clinical workflows like tumor boards, prior authorization, trial matching, and treatment adherence, differentiate it from Tempus’s broader, large-scale data-centric model. This makes GeneSilico particularly well-suited for integrated, local, and scalable deployment at the point-of-care.
- Legacy NGS competition - gSage competes with Foundation Medicine, Guardant Health, and BostonGene by offering highly cancer-specific, targeted panels optimized for operational efficiency and real-world data, especially in international markets. While Foundation and Guardant lead with broad genomic profiling and FDA-approved assays, gSage’s AI-driven, precise insights focus on local clinical relationships and high-quality, cancer-focused data. gSage upcoming launch in the US and focus on training AI on complex Indian data give it a competitive edge in delivering scalable, accurate, and tailored precision oncology solutions for diverse healthcare settings.
- Competition against tech giants - Microsoft, Google, and Meta are investing heavily in AI for oncology, focusing on early detection, diagnostics, and clinical data analysis. However, gSage has a distinct competitive advantage in precision oncology because it leverages high-quality, disease-specific data and deep clinical relationships in India, enabling more accurate and actionable insights. Its AI models, trained on complex, real-world data from India, are highly robust and adaptable, providing a strong foundation for global scalability. Additionally, gSage plans to launch its open oncology AI in the US later this year, allowing for rapid adoption of precision oncology practices in the US market. This US launch will also benefit from the detailed, high-quality genomic data we are gathering in India, further enhancing gSage’s AI accuracy and effectiveness across diverse healthcare environments.